Conditioned apomorphine-induced turning in 6-OHDA-lesioned rats.
Apomorphine-induced turning has been used to evaluate the extent of unilateral nigrostriatal denervation after 6-hydroxydopamine (6-OHDA) lesions and subsequent functional striatal reinnervation by catecholaminergic grafts. It has been noted that the pregraft rotational pattern is usually double peaked and that fetal ventral mesencephalic grafts or dopaminergic drugs will alter the second peak but leave the first relatively unchanged. We hypothesized that the first peak may be the result of factors extrinsic to the nigrostriatal dopamine system, specifically a conditioned turning response, and would, therefore, be unperturbed by the above treatments which increase dopaminergic (DA) inputs. This was investigated by injecting 6-OHDA, unilaterally, into the nigrostriatal pathway of several groups of young Fisher 344 rats. One experimental group was repeatedly tested with 0.05 mg/kg apomorphine and the rotations quantified. A second group received similar injections of apomorphine but were prevented from rotating. Vehicle control animals were also studied for both of the above experimental groups. Subsequent to the above treatment, all animals were tested unrestrained repeatedly on apomorphine. Our results support the conditioned response hypothesis in that the first peak is not present with the initial unrestrained apomorphine behavioral trial but is present upon the second and subsequent unrestrained trials. Moreover, the restrained but apomorphine-injected rats, as well as the control animals, manifest no first peak upon their first freely moving apomorphine test; the second and subsequent unrestrained apomorphine trials, in these groups, do manifest a first peak.(ABSTRACT TRUNCATED AT 250 WORDS)
Hudson
J L
JL
Department of Pharmacology, University of Colorado Health Sciences Center, Denver 80262.
Fong
C S
CS
Boyson
S J
SJ
Hoffer
B J
BJ
D000818:Animals; D001058:Apomorphine / Q000494:pharmacology*; D003214:Conditioning, Classical / Q000187:drug effects*; D004298:Dopamine / Q000502:physiology; D004777:Environment; D008297:Male; D016627:Oxidopamine / Q000494:pharmacology*; D051381:Rats; D011916:Rats, Inbred F344; D012149:Restraint, Physical; D013239:Stereotyped Behavior / Q000187:drug effects*; D013312:Stress, Physiological / Q000523:psychology
D016627:Oxidopamine; D001058:Apomorphine; D004298:Dopamine